Celiac Disease Treatment Market Analysis

Global Celiac Disease Treatment Market Overview

Celiac Disease Treatment Market Size was valued at USD 0.5 Billion in 2022. The Celiac Disease, Treatment market industry is projected to grow from USD 0.55 Billion in 2023 to USD 1.28 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.03% during the forecast period (2023 - 2032).Increased prevalence of diabetes leading to celiac diseases and rising trials for drugs for celiac disease treatment and key market drivers enhancing the market growth. 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

The growth rate of the celiac disease treatment market is being driven by the increasing prevalence of celiac disease. Cases of celiac disease are increasing as the prevalence of diabetes rises across all age categories. Diabetes is a chronic blood glucose disease because the body cannot regenerate blood glucose. Government and healthcare organizations are increasingly concerned about the correlation between diabetes and celiac disease, as diabetes increases the risk of developing celiac disease. The rise in these instances has increased the demand for gluten-free products, thereby expanding the market.

Greater public and professional awareness of celiac disease symptoms, risk factors, and the importance of early diagnosis has led to an increase in the number of individuals seeking medical care and receiving an accurate diagnosis. Consequently, the demand for alternative treatments for celiac disease increases. Gluten-free products are in high demand as celiac disease and gluten sensitivity become more prevalent. As a consequence, the gluten-free food industry has grown substantially and now offers a wide variety of gluten-free options. This growth in the gluten-free product industry indirectly benefits the celiac disease treatment market.

The increasing prevalence of therapeutic products in economically developed regions drives market expansion. Additionally, favorable government policies throughout the Western world, an increase in clinical trials for medicines to treat celiac disease, and an increase in the consumption of gluten-rich foods such as bread, pizza, and soda all contribute to the spread of celiac diseases. Gluten protein consumption may increase as a result of faster service in restaurants offering ready-to-eat packaged foods, beverage addiction, unhealthy food, lifestyle changes, and rising disposable income. New celiac disease treatment opportunities will emerge as a result of technological progress, rising modernization in the healthcare sector, and research and development efforts. Thus driving market revenue for Celiac Disease Treatment.

In May 2023: Topas Therapeutics has initiated a Phase IIa clinical trial of TPM502 to treat celiac disease, an autoimmune disorder, in May 2023. The placebo-controlled, double-blind, randomized, multicenter study will evaluate the tolerability, safety, and pharmacodynamic effects of two dose-escalating administrations of TPM502 in cohorts. In the trial, symptom severity and immune tolerance will be evaluated following gluten exposure. The development of TPM502 represents a major advancement in our immune tolerance-based clinical pipeline and exemplifies our mission to provide novel disease-modifying therapeutics to patients with limited pharmacological options.

In May 2023, Topas Therapeutics will be treating Autoimmune Celiac disease with TPM502. It is expected that a double-blind, placebo-controlled, multicenter trial intended for a randomized phase ĩ, which would analyze the safety, tolerability and pharmacodynamic consequences of two dose-escalating administrations of TPM502 to different cohorts is anticipated. At the time of the test, symptom severity and immune tolerance are measured post-gluten exposure. This paper outlines the development of TPM502 as a new disease-modifying agent engineered to cure an orphan condition in patients without effective therapies.

Larazotide acetate (INN-202), developed by Innovate Biopharmaceuticals, could be used as a potential therapeutic for Celiac Disease by June 2022. The small intestine is targeted at tight junctions by this synthetic peptide. With celiac disease, this complex interplay is lost such that gluten peptides bypass and activate bacteria, leading to immune responses on the intestinal lining, which kill it.

Therefore, Innovative Biopharmaceuticals Inc. announced the first patient enrollment into its Phase III clinical trial CeD LA 3001 for Larazotide acetate as a Drug candidate against Celiac disease in August 2019.

BioLineRx recently announced the initiation of a phase 2b clinical trial of their lead compound BL-7010 as a Potential Therapeutic against celiac disease. This research evaluates both efficacy and safety profile of BL-7010 when given at doses reducing symptoms associated with glutening and gut inflammation seen among patients with celiac living.

EmpowerDX introduced the Easy At Home Genetic Risk Test for Celiac Disease on May 5th,2022. Hence, the forecast period would witness growth due to the increasing acceptance rate of home test kits.

Celiac Disease Treatment Market Trends

• Growing cases of celiac disease are driving the market growth

Market CAGR for celiac disease treatment is being driven by the rising cases of celiac diseases. The rise in the generality of diabetes in all age groups is increasing the case of celiac disease. Diabetes is a blood-glucose chronic disease because the body cannot produce the reacquired blood glucose. Increasing cases of diabetes have increased the concerns in government and healthcare organizations as these leads to the risk of celiac disease. The increase in these cases has increased the demand for the application of gluten-free products, thus growing the market.

Celiac disease is an illness that is autoimmune, in which the protein gluten hampers the membrane of the small intestine. Gluten is available in grains like rye, wheat, and barley. Consumption of gluten leads to an immunological reaction that hampers the villi of the small intestine, which is a small finger-like projection in the small intestine that promotes absorption. The capability of the body for absorbing nutrients, proteins, lipids, carbs, vitamins, and minerals is disturbed by the damage caused to villi in the small intestine, leading to malnutrition. Celiac disease is a genetic auto-immune disorder that leads to many other diseases like low bone density, infertility, neurology, and certain cancers. There is no drug present on the market that can treat celiac disease; the symptoms include abdominal pain, low bone density, weight loss, and headache. If the symptoms are undiagnosed and not treated well can lead to neurological dysfunction, osteoporosis, anemia, and infertility.

The growing inclusion of therapeutic products in economically developed regions is fueling market growth. Also the growing favorable government policies throughout the Western world, rising clinical trials for drugs against celiac disease, and increase in consumption of foods like bread, pizza, and coke, which are high in gluten protein, lead to celiac diseases. The fast-tracking in restaurants offering ready-to-eat packaged foods, beverages addiction, junk food, altering lifestyle, and rising disposable income can increase the consumption of gluten protein. The technological advancement and rising modernization in the healthcare section and research & development activities will create new celiac disease treatment opportunities. Thus, driving the Celiac Disease Treatment market revenue.

The constrained availability of the option of treatment in the market, the absence of specific drugs for the treatment of the disease, and most of the celiac disease cases remaining misdiagnosed are the main factors restraining the market growth of celiac disease treatment.

Celiac Disease Treatment Market Segment Insights

Celiac Disease Treatment Treatment Type Insights

The Celiac Disease Treatment market segmentation, based on treatment type, includes Gluten Free Diet, Vitamin and Minerals Supplements, and Medical Therapies. The vitamin and mineral supplement segment dominates the market, accounting for the largest market revenue as vitamin and mineral fortification becomes essential when wheat is excluded from the diet, and many of the gluten-free meals are not fortified with the vitamins and minerals like iron, zinc, magnesium, phosphorous, and vitamin B. supplement of vitamins and minerals provides 100% of the recommended levels of these nutrients. Therefore, patients are adopting vitamin and mineral supplements for effective celiac disease treatment. The key market players are investing in clinical trials and R&D for different medical therapies for celiac disease treatment.

Figure 1: Celiac Disease Treatment Market, by Treatment Type, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Celiac Disease Treatment End User Insights

The Celiac Disease Treatment market segmentation, based on end users, includes Hospitals and Clinics, Research Centers, and Others. The research center segment dominates the market as there has been a prominent increase in investments in research and development for treating celiac diseases. The key market players are investing in promising treatments and different drug clinical trials to give effective results.

Celiac Disease Treatment Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Celiac Disease Treatment market dominates the celiac disease treatment market because of the increasing cases of celiac diseases, the availability of the major market players, and the growth in refined healthcare expenses in the North American region. The major contributor to celiac disease treatment is the US.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: CELIAC DISEASE TREATMENT MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's Celiac Disease Treatment market accounts for the second-largest market share because of the occurrence of market players and the rising government support for vaccine development. Further, the German Celiac Disease Treatment market held the largest market share, and the UK Celiac Disease Treatment market was the fastest-growing market in the European region.

The Asia-Pacific Celiac Disease Treatment Market is expected to grow at the rapid CAGR from 2023 to 2032. This is due to increasing awareness about the disease and increasing population in the region. Moreover, China’s Celiac Disease Treatment market held the largest market share, and the Indian Celiac Disease Treatment market was the fastest-growing market in the Asia-Pacific region.

Celiac Disease Treatment Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to spread their product lines, which will help the Celiac Disease Treatment market grow even more. Market participants are also undertaking a various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Celiac Disease Treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Celiac Disease Treatment industry to benefit clients and increase the market sector. In recent years, the Celiac Disease Treatment industry has offered some of the most significant advantages to medicine. Major players in the Celiac Disease Treatment market, including General Mills Inc., Innovate Biopharmaceutical, ActoBio, Glenmark Pharmaceuticals Company Ltd., Takeda Pharmaceuticals Company Ltd., Zydus Pharmaceuticals Inc., BioLineRx, West-Ward Pharmaceuticals Company Ltd., Calypso Biotech SA, and others, are attempting to increase market demand by investing in R&D operations.

ActoBio, founded in 2006 and headquartered in Ghent, Belgium, is a biotechnological company at a clinical-stage developing a new class of therapeutic agents created on the ActoBiotics platform. The company targets microbe-based, mainly designed agents which can express and locally offer potential disease-modifying therapeutics at disease sites, including the intestine, the nasopharynx, and the mouth, to treat a range of disorders. The company invests largely in research and development to develop new and effective products. In August 2019, ActoBio Therapeutics Inc., which is a fully owned subsidiary of Intrexon Corporation, announced that the US Food and the Drug Administration (FDA) has granted an Investigational New Drug (IND) application for the AG017, which is an orally-delivered drug for treating celiac disease.

Innovate Biopharmaceutical, founded in 2012, is a US-based clinical-stage company emphasizing creating novel gastroenterology medicines. Its drug portfolio consists of INN-202, a tight junction regulator that assists in restoring open junction to a normal state and is in phase 3 trials for Celiac Disease (CeD), and INN-108, which is a small molecule in phase 2 trials for Inflammatory Bowel Disorders, mild to moderate Ulcerative Colitis and a GI orphan diseases. INN-108 is a pro-drug that is activated only colon, and the convenience of liquid is important for children and the aging population. In August 2019, Innovative Biopharmaceuticals Inc. announced the first patient enrollment in its Phase III clinical trial, CeD LA 3001, for Larazotide acetate, a drug candidate for treating celiac disease. 

Key Companies in the Celiac Disease Treatment market include

• General Mills Inc.


• Innovate Biopharmaceutical


• ActoBio


• Glenmark Pharmaceuticals Company Ltd.


• Takeda Pharmaceuticals Company Ltd.


• Zydus Pharmaceuticals Inc.


• BioLineRx


• West-Ward Pharmaceuticals Company Ltd.


• Calypso Biotech SA

March 2022:KaraMD announced Pure Health Apple Cider Vinegar Gummies, a vegan gummy aimed to aid ketosis, digestion regulation, weight management, and encourage greater levels of energy.

January 2022:Solace Nutrition, a US-based medical nutrition company, bought R-Kane Nutritionals' assets for an unknown sum. This asset acquisition enables Solace Nutrition to develop synergy between both brands, accelerate growth, and establish a position in an adjacent nutrition sector. R-Kane Nutritionals is a firm established in the United States that specializes in high-protein meal replacement products for weight loss.

August 2019:The researchers from the Massachusetts General Hospital and the Walter and Eliza Hall Institute in Australia came to know that gluten-specific CD4+ T cells are quickly reactivated by the antigen-exposure likely causing celiac disease-associated gastrointestinal symptoms. This innovation is anticipated to provide diagnostic blood tests for celiac disease.

May 2023: Anokion has announced positive results from a completed Phase I trial examining KAN-101 as a treatment for celiac disease. The ACeD trial was a randomized, double-blind, placebo-controlled investigation of gluten-free diets in 41 individuals with celiac disease across two cohorts of single-ascending dose and multi-ascending dose. Early study results demonstrated the safety and tolerability of KAN-101, as well as the induction of functional tolerance in gliadin-specific T cells in response to gluten challenge. Unlike conventional broad-spectrum immunosuppressants, KAN-101 can specifically target immune system components responsible for gluten-related immune reactions.

Celiac Disease Treatment Market Segmentation

Celiac Disease Treatment Treatment Type Outlook

• Gluten-Free Diet


• Vitamin and Minerals Supplements


• Medical Therapies

Celiac Disease Treatment End User Outlook

• Hospitals and Clinics


• Research Centers


• Others

Celiac Disease Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America